Month: June 2025

Safe, Consistent Iron Delivery in Serum-Free Systems with Optiferrin® Recombinant Transferrin

By

Overview Efficient iron delivery plays a critical role in maintaining cell health, supporting proliferation, and maximizing therapeutic productivity. However, serum-derived transferrin introduces variability, regulatory risk, and the potential for contamination. This application note demonstrates how Optiferrin, a recombinant transferrin for iron delivery in serum-free media, provides a consistent and animal-origin-free alternative. It mirrors native transferrin …

Why Border Disruptions Threaten Blood-Derived Raw Materials—and What Biomanufacturers Can Do About It

By

Reading time: 4 minutes What happens when your biologics pipeline depends on the reliability of an international border? For many manufacturers still using plasma-derived components like albumin or transferrin, that’s not a hypothetical. It’s baked into their supply chain. Across the U.S.–Mexico border, more than 50 plasma centers depend on daily crossings from Mexican nationals …

Low-DMSO Cryopreservation of MSCs with Optibumin 25 Recombinant Albumin

By

Overview This application note demonstrates the use of Optibumin® 25—an animal-origin-free recombinant HSA—for low-DMSO cryopreservation of UC-MSCs. Optibumin matched or outperformed blood-derived HSA, even at DMSO levels as low as 1%, supporting safer, regulatory-friendly workflows for cell therapy manufacturing. Key Findings Maintains MSC viability at 1–2.5% DMSO Reduces apoptosis vs. no-albumin controls Performs as well …